Preclinical in vivo proof of mechanism study of selective mTORC1 inhibitors

• Forschungsstelle: INNOSUISSE
• Projektnummer: 120.434 IP-LS
• Projekttitel Englisch: Preclinical in vivo proof of mechanism study of selective mTORC1 inhibitors

Schlüsselwörter (Englisch)

Life sciences, Pharmaceuticals

Abstract (Englisch)

Increased activity of mammalian target of rapamycin complex 1 (mTORC1) is linked to multiple disorders. We identified ten small compounds that selectively and efficiently inhibit mTORC1 in vitro with an innovative mode of action. We now aim to achieve preclinical proof of mechanism in mice.